Posted by Michael Wonder on 16 Dec 2025
US FDA approves LIB Therapeutics’ Lerochol (lerodalcibep-liga) for adults with elevated LDL-cholesterol
15 December 2025 - Lerochol expected to be available in the US in spring 2026.
LIB Therapeutics today announced the US FDA has approved Lereochol (lerodalcibep-liga) injection for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia.
